Home › Research › Brain scans and imaging
18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial
Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, Hasselbalch S, Law I et al.. Annals of neurology, 2010-09-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective The most widely studied positron emission tomography ligand for in vivo beta-amyloid imaging is (11)C-Pittsburgh compound B ((11)C-PIB). Its availability, however, is limited by the need for an on-site cyclotron. Validation of the (18)F-labeled PIB derivative (18)F-flutemetamol could significantly enhance access to this novel technology. Methods Twenty-seven patients with early-stage clinically probable Alzheimer disease (AD), 20 with amnestic mild cognitive impairment (MCI), and 15 cognitively intact healthy volunteers (HVs) above and 10 HVs below 55 years of age participated. The primary endpoint was the efficacy of blinded visual assessments of (18)F-flutemetamol scans in assigning subjects to a raised versus normal uptake category, with clinical diagnosis as the standard of truth (SOT). As secondary objectives, we determined the correlation between the regional standardized uptake value ratios (SUVRs) for (18)F-flutemetamol and its parent molecule (11)C-PIB in 20 of the AD subjects and 20 of the MCI patients. We also determined test-retest variability of (18)F-flutemetamol SUVRs in 5 of the AD subjects. Results Blinded visual assessments of (18)F-flutemetamol scans assigned 25 of 27 scans from AD subjects and 1 of 15 scans from the elderly HVs to the raised category, corresponding to a sensitivity of 93.1% and a specificity of 93.3% against the SOT. Correlation coefficients between cortical (18)F-flutemetamol SUVRs and (11)C-PIB SUVRs ranged from 0.89 to 0.92. Test-retest variabilities of regional SUVRs were 1 to 4%. Interpretation (18)F-Flutemetamol performs similarly to the (11)C-PIB parent molecule within the same subjects and provides high test-retest replicability and potentially much wider accessibility for clinical and research use.
What this study adds
Evidence grade: Low
In this small phase 2 study, blinded readers rated flutemetamol PET scans as showing raised amyloid in "25 of 27 scans from AD subjects and 1 of 15 scans from the elderly" healthy volunteers. Reported effect size: 93.1%; 93.3%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Vandenberghe, R., Van Laere, K., Ivanoiu, A., Salmon, E., Bastin, C., Triau, E., et al. (2010). 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Annals of neurology. https://doi.org/10.1002/ana.22068
Vancouver
Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Annals of neurology. 2010. doi:10.1002/ana.22068. PMID: 20687209.
BibTeX
@article{vandenberghe2010-20687209,
author = {Vandenberghe, R. and Van Laere, K. and Ivanoiu, A. and Salmon, E. and Bastin, C. and Triau, E. and Hasselbalch, S. and Law, I. and others},
title = {{18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial}},
journal = {Annals of neurology},
year = {2010},
doi = {10.1002/ana.22068},
pmid = {20687209},
url = {https://doi.org/10.1002/ana.22068}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Validation of the (18)F-labeled PIB derivative (18)F-flutemetamol could significantly enhance access to this novel technology.
- The primary endpoint was the efficacy of blinded visual assessments of (18)F-flutemetamol scans in assigning subjects to a raised versus normal uptake category, with clinical diagnosis as the standard of truth (SOT).
- Results Blinded visual assessments of (18)F-flutemetamol scans assigned 25 of 27 scans from AD subjects and 1 of 15 scans from the elderly HVs to the raised category, corresponding to a sensitivity of 93.1% and a specificity of 93.3% against the SOT.
Why it matters
In this small phase 2 study, blinded readers rated flutemetamol PET scans as showing raised amyloid in "25 of 27 scans from AD subjects and 1 of 15 scans from the elderly" healthy volunteers. Against clinical diagnosis, that gave a sensitivity of 93.1% and a specificity of 93.3%. Its uptake values correlated closely with the established tracer PIB in the same people (r 0.89–0.92), and repeat scans in 5 patients varied by 1–4%. The authors say it "performs similarly" to PIB and, unlike PIB, does not need "an on-site cyclotron", but the study does not report a visual-read result for its 20 MCI patients and did not check scans against brain tissue.
New to this subject? Start with our plain-English guide: Brain scans & tests →
Study details
- Effect size93.1%; 93.3%
- Evidence strengthLow
How this study scored 71/100
Published in a leading specialty journal, and it is a mid-stage phase 2 trial. Scored zero for sample size because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Annals of neurology) |
| Journal's citation record | 3 / 4 | Annals of Neurology: journal h-index 437 (OpenAlex, 2026-10-29) |
| Study design | 8 / 12 | A mid-stage phase 2 trial (from PubMed type “Clinical Trial, Phase II”) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2010 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 1 / 2 | Blinded or placebo-controlled (as stated in the record) |
| Times cited | 6 / 7 | Cited 649 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 36.1 citations a year over 18 year(s) since 2010 |
| Impact for its field and year | 5 / 6 | Cited 29.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 51 other studies in this library |
| Still being cited | 3 / 4 | Cited 57 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author David James Brooks: h-index 158 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Imperial College London: institution h-index 1,744 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 10 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 20687209) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 71 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
51 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Brain scans and imaging from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.